Latest in News & Research
FDA Approves Emrosi for Rosacea in Adults
Phase 3 trials show significant reduction in total lesion count versus Oracea and placebo
Topical Human Platelet Extract Noninferior for Photoaging of Hands
HPE performs as well as topical vitamin C for improvement in brown spot fractional area, wrinkle fractional area, luminosity
COVID-19 Linked to Long-Term Risk for Autoimmune, Autoinflammatory Disease
Demographic factors, including sex, age younger than 40 years, age 40 years and older, showed diverse associations with risk for outcomes
Cutaneous Malignant Melanoma Incidence Increasing Among the Elderly
Age-adjusted CMM incidence rate was 0.99 per 1,000 from 2012 to 2016, marking an increase from previous years
Travel Time to Tanning Facilities Negatively Linked to Melanoma Incidence
Six high-risk clusters were identified with respect to county-level melanoma rate
Launch Alert: FDA Approves Emrosi for Inflammatory Lesions of Rosacea
The approval marks the first oral minocycline formulation for the papules and pustules characteristic of the condition
Risk for Psoriasis Increased With Immune Checkpoint Inhibitor Use in Cancer
ICI users have about a twofold increase in risk for developing psoriasis, with findings consistent across all follow-up intervals
Pain Prevalent Among Mohs Surgeons, Reported by 88.7 Percent
Male surgeons less often complain of upper back pain, but more often report lower back pain than female surgeons
New Set of Risk Factors Can Boost Detection of Suspicious Skin Lesions
C4C risk score achieved sensitivity of 80.46 ± 2.50 percent and specificity of 62.09 ± 1.90 percent, outperforming other models
First Cases of Sexually Transmitted Ringworm Reported in the U.S.
All five known cases involved men who have sex with men; the rashes cleared up with antifungal treatments
Using Filtering Function Before Skin Biopsy Can Reduce Benign-to-Malignant Ratio
Health care system in Denmark employing filtering function before biopsy achieved low benign-to-malignant ratio over 15 years, but at high cost
Potential Genetic Link ID'd Between Thyroid Disease, Alopecia Areata
Significant genetic predictions of alopecia seen with hypothyroidism, Hashimoto thyroiditis, and subacute thyroiditis
Total, Facial Vitiligo Area Scoring Indices Effectively Differentiate Vitiligo Patients
Improvements of 30 percent in T-VASI and 50 percent in F-VASI reflect meaningful repigmentation between baseline, week 24
FDA Approves EBGLYSS for Moderate-to-Severe Atopic Dermatitis in Adults and Adolescents
The IL-13 inhibitor offers a new first-line biologic treatment option for moderate-to-severe atopic dermatitis not well-controlled with topicals
Remote Cutaneous Confocal Microscopy Has Good Diagnostic Accuracy for Skin Malignancy
Sensitivity of remote CCM was 89 percent, specificity was 64 percent for detection of malignancy
Superior Drug Survival Seen for Dupilumab in Pediatric Patients With AD
Risk for drug discontinuation higher due to ineffectiveness, adverse events for MTX, CsA versus dupilumab
Relationship Suggested Between Hyperhidrosis, Sensitive Skin
Sensitive skin occurred on body sites that were and were not affected by hyperhidrosis
Benzene Exposure Results From Benzoyl Peroxide Drug Product Use
Benzene concentrations detected in 111 over-the-counter BPO drug products that were tested, maintained at room temperature
Risk for Second Melanoma Up for Those With First Melanoma Diagnosis
Melanoma less common among racial and ethnic minorities, but they still have increased rate of second primary melanoma
Disease-Specific Survival Equal for Mohs, Wide Local Excision in Cutaneous Leiomyosarcoma
DSS similar with Mohs micrographic surgery, wide local excision treatment; findings persist in adjusted analysis
Serum, Tissue Levels of CXCL9 Elevated in Nonsegmental Vitiligo
Serum and tissue levels of CXCL9 are reduced after 12 weeks of narrowband ultraviolet B phototherapy
Bimekizumab Safe, Efficacious Over Two Years for Hidradenitis Suppurativa
Clinically meaningful efficacy outcomes observed at one year maintained to two years of treatment
Long-Term Efficacy for Lebrikizumab Seen in Moderate, Severe Eczema
Long-term efficacy seen for lebrikizumab every two weeks or every four weeks in moderate-to-severe atopic dermatitis
24 of 1274